Study supports repeat colonoscopy after positive interval FIT following colonoscopy
-
June 12
Patients with a positive interval FIT had a higher rate of post-colonoscopy colorectal cancer than those who tested negative or weren't tested, according to a British Columbia cohort study.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Study supports repeat colonoscopy after positive interval FIT following colonoscopy
-
by Olivia Anderson
Patients with a positive interval FIT had a higher rate of post-colonoscopy colorectal cancer than those who tested negative or weren't tested, according to a British Columbia cohort study.
GLP-1 agonists linked to lower opioid use in chronic pancreatitis
-
by Doug Brunk
In a matched real-world cohort, treated patients started chronic opioids less often and were less likely to develop opioid use disorder.
Low FODMAP diet may offer lasting symptom relief in celiac disease
-
by Doug Brunk
Patients reported sustained improvement five years on, though between-group differences did not reach statistical significance.
Hepatic steatosis tied to vulnerable coronary plaque, higher cardiac risk
-
by Doug Brunk
CT imaging from the PROMISE trial links hepatic steatosis to lipid-rich plaque and a roughly 1.7-fold higher rate of major adverse cardiovascular events, independent of standard risk factors.
How do advanced IBD therapies compare for serious infection risk?
-
by Julia Cipriano
Across five drug classes for inflammatory bowel disease, concomitant corticosteroids doubled the serious infection risk, regardless of which therapy they accompanied.
